Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BTG International (BTG) has sold out its treatment for acute migraine attacks, AP-1531 to Ariel Pharmaceuticals.
Subscribe to our email newsletter
AP-1531 is a potent and selective EP4 receptor antagonist that targets PGE2-EP4 binding which may treat migraines.
In earlier studies, AP-1531 has demonstrated positive results in several disease models of migraine and acute pain and inflammation.
Ariel Pharma president and CEO Steve Orndorff said they believe AP-1531 will validate their business model of in-licensing clinic-ready drugs in acute care clinical indications to expeditiously build value for their shareholders.